Metraipolis › archive › dc_8f177b0fcdbd
Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis — Europe PMC PMID:41695633
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41695633
- DOI
- 10.3389/fneur.2026.1738815
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T10:10:11.841Z
- SHA-256 of the archived text
78310de0277f4eadbbb36bebbabf4d2f942574823840cc83820030a88f75d076- Stable URL of this page
https://metraipolis.com/documento/dc_8f177b0fcdbd
How to cite
Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis — Europe PMC PMID:41695633 — Europe PMC (en), https://europepmc.org/article/MED/41695633 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8f177b0fcdbd (Metraipolis archive dc_8f177b0fcdbd, sha256 78310de0277f4eadbbb36bebbabf4d2f942574823840cc83820030a88f75d076)
BibTeX
@misc{dc8f177b0fcdbd,
title = {Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis — Europe PMC PMID:41695633},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41695633},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8f177b0fcdbd; sha256 78310de0277f4eadbbb36bebbabf4d2f942574823840cc83820030a88f75d076},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41695633. Agents can read the archived copy with the MCP tool read_document.